Zidesamtinib is a potent, selective, orally active and blood-brain barrier permeable inhibitor of multiple ROS1 fusion and resistance mutations, with IC50 values of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and does not inhibit TRK.May be useful in studies related to non-small cell lung cancer and other solid tumors.
Zidesamtinib is a potent, selective, orally active and blood-brain barrier permeable inhibitor of multiple ROS1 fusion and resistance mutations, with IC50 values of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and does not inhibit TRK.May be useful in studies related to non-small cell lung cancer and other solid tumors.
Zidesamtinib is a potent, selective, orally active and blood-brain barrier permeable inhibitor of multiple ROS1 fusion and resistance mutations, with IC50 values of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and does not inhibit TRK.May be useful in studies related to non-small cell lung cancer and other solid tumors.
Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity.
Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity.
Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity.
Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively.
Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively.
Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively.
Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively.
Zilucoplan is a 15 amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor that specifically targets C5, a component of the terminal complement activation pathway, thereby preventing the cleavage of C5 by C5 converting enzyme into complement components C5a and C5b, and thus preventing the downstream assembly and activity of the...